ARATANA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aratana Therapeutics - PETX
NEW ORLEANS--(BUSINESS WIRE)--May 3, 2019--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aratana Therapeutics (NasdaqGM: PETX) (“Aratana”) to Elanco Animal Health (NYSE: ELAN) (“Elanco”). Under the terms of the proposed transaction, shareholders of Aratana will receive only 0.1481 shares of Elanco and one contingent value right valued at $0.25 for each share of Aratana that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( firstname.lastname@example.org ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-petx/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190503005528/en/
CONTACT: Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner, 855-768-1857
KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL CONSUMER PETS
SOURCE: Kahn Swick & Foti, LLC
Copyright Business Wire 2019.
PUB: 05/03/2019 05:39 PM/DISC: 05/03/2019 05:39 PM